Design Therapeutics (DSGN) Expected to Announce Earnings on Monday

Design Therapeutics (NASDAQ:DSGN) is expected to announce its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Design Therapeutics to post earnings of ($0.37) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Design Therapeutics Stock Down 0.4%

NASDAQ DSGN opened at $10.05 on Friday. The company has a market cap of $572.45 million, a PE ratio of -8.45 and a beta of 1.63. Design Therapeutics has a 52 week low of $2.60 and a 52 week high of $11.14. The firm’s 50-day simple moving average is $9.96 and its two-hundred day simple moving average is $8.15.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Vivo Capital LLC bought a new position in Design Therapeutics in the 4th quarter worth about $15,129,000. RA Capital Management L.P. lifted its position in Design Therapeutics by 207.2% during the fourth quarter. RA Capital Management L.P. now owns 1,461,381 shares of the company’s stock valued at $13,708,000 after purchasing an additional 985,682 shares during the last quarter. Woodline Partners LP purchased a new position in Design Therapeutics in the 1st quarter worth approximately $2,492,000. Invesco Ltd. grew its stake in Design Therapeutics by 1,995.8% in the 4th quarter. Invesco Ltd. now owns 305,757 shares of the company’s stock worth $2,868,000 after buying an additional 291,168 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Design Therapeutics in the 4th quarter worth $2,115,000. 56.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Design Therapeutics in a research note on Wednesday, January 21st. Oppenheimer assumed coverage on shares of Design Therapeutics in a report on Wednesday, January 7th. They set an “outperform” rating and a $18.00 target price on the stock. Craig Hallum began coverage on Design Therapeutics in a research report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 target price on the stock. Royal Bank Of Canada upgraded Design Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $6.00 to $13.00 in a research report on Thursday, November 20th. Finally, Leerink Partners set a $14.00 price objective on Design Therapeutics and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.